Texas Permanent School Fund Corp raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 33.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 27,281 shares of the company’s stock after purchasing an additional 6,872 shares during the quarter. Texas Permanent School Fund Corp owned 0.09% of Medpace worth $11,236,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rise Advisors LLC bought a new stake in Medpace during the first quarter valued at about $27,000. Mather Group LLC. bought a new stake in Medpace during the 1st quarter worth approximately $28,000. Fidelis Capital Partners LLC bought a new position in shares of Medpace in the first quarter worth approximately $31,000. DT Investment Partners LLC purchased a new stake in shares of Medpace in the second quarter worth $41,000. Finally, J.Safra Asset Management Corp raised its position in shares of Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.
Medpace Price Performance
Shares of NASDAQ MEDP opened at $339.38 on Tuesday. The stock has a market capitalization of $10.52 billion, a P/E ratio of 34.60, a PEG ratio of 1.74 and a beta of 1.36. Medpace Holdings, Inc. has a 1-year low of $227.21 and a 1-year high of $459.77. The business’s 50 day moving average is $389.35 and its two-hundred day moving average is $395.07.
Wall Street Analysts Forecast Growth
A number of research firms have commented on MEDP. William Blair reissued an “outperform” rating on shares of Medpace in a report on Tuesday, July 23rd. Robert W. Baird lowered their price target on Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a report on Wednesday, July 24th. TD Cowen cut their price objective on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Mizuho started coverage on shares of Medpace in a report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research note on Wednesday, July 24th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $423.00.
View Our Latest Analysis on Medpace
Medpace Company Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Featured Articles
- Five stocks we like better than Medpace
- How to Find Undervalued Stocks
- 3 Stocks That Make Good Short-Squeeze Candidates
- What Are Growth Stocks and Investing in Them
- Why Block’s Key Components Make It a Solid Investment Choice
- What Is WallStreetBets and What Stocks Are They Targeting?
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.